Chardan Capital Sets Target Price of $60 for Monopar Therapeutics

Summary

Chardan Capital has begun coverage on Monopar Therapeutics (NASDAQ: MNPR) with a ‘buy’ rating and a target price of $60, indicating an 82.59% upside potential. Other analysts have mixed ratings, with a general consensus of ‘moderate buy’ and a target price of $56.50. Monopar’s stock opened at $32.86, with a market cap of $201.1 million. The company reported a quarterly EPS of ($0.38), exceeding expectations. Monopar focuses on developing cancer treatment drugs, with its main candidate currently in clinical trials.Market Beat

Impact Analysis

This event is at the company level as it involves Monopar Therapeutics’ financial analysis and stock rating by Chardan Capital. The information node is Chardan Capital’s ‘buy’ rating and $60 target price, which suggests confidence in Monopar’s future prospects, likely due to positive developments in its clinical trials for cancer treatment drugs. The first-order effects include potential investor optimism and increased buying pressure that could drive the stock price closer to or beyond the target. Additionally, the positive earnings surprise may further bolster investor confidence. The second-order effects might involve increased interest from institutional investors and potential partnerships or funding opportunities as the company gains more visibility. Investment opportunities could include buying Monopar stock to capitalize on the anticipated price increase towards the target price. However, risks include the inherent uncertainties in clinical trial outcomes and potential regulatory hurdles that could impact stock performance.Market Beat